Basic information of drug: DB05408
| Drug id | DB05408 |
| Drug name | Emricasan |
| Description | Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. |
| State | solid |
| Cas number | 254750-02-2 |
| Synonyms | Emricasan Emricasán Emricasanum |
| Sequences | None |
| Indication | Investigated for use/treatment in hepatitis (viral, C), liver disease, and transplantation (organ or tissue). |
| Pharmacodynamics | None |
| Mechanism of action | IDN-6556 significantly improves markers of liver damage in patients infected with the Hepatitis C virus (HCV), an infection that affects up to 170m patients worldwide. IDN-6556 represents a new class of drugs that protect the liver from inflammation and cellular damage induced by viral infections an... |
| Metabolism | None |
| Toxicity | None |